Navigation Links
Frost & Sullivan Market Study Gives 'Thumbs Up' for Pepex™ Trio™ One-Click™ Blood Glucose Meter
Date:12/21/2010

ST. LOUIS, Dec. 21, 2010 /PRNewswire/ -- Research firm Frost & Sullivan, a leading international healthcare consulting company, released a market study analyzing and estimating the demand for Pepex Biomedical Inc.'s new biosensor technology for blood glucose monitoring for diabetes sufferers worldwide.  The researchers interviewed diagnosed diabetics, diabetes educators, endocrinologists, and manufacturers of biosensors, blood glucose meters, or other clinical diagnostic or patient monitoring equipment suppliers for the study.  The Frost & Sullivan report concluded that the Pepex Trio technology has the "potential as a new standard for measuring blood glucose levels."

The analysts noted three areas of opportunity for innovation in their review of diabetes monitoring:

  • Improved meter accuracy and reliability to assure proper insulin dosages
  • Ease of use for improved testing compliance
  • Reduction in the cost of the commonly used single-use disposable test strips

Additional needs are the users' desire for improved meter convenience, minimizing operator technique, increased speed of results and a compact meter size because many diabetics are required to carry their meters for around-the-clock testing.

Frost & Sullivan commented that, "Pepex is well-positioned to capitalize on (these needs) with a truly novel approach that may improve accuracy of readings and also provide other benefits to patients in terms of ease-of-use and lower costs."  This is important because, "Recently, the FDA petitioned the International Organization for Standardization to change the allowable error rate for BGMs, currently at plus or minus 20 percent, to be more accurate.  The wide error rate has been a concern for many years as it can leave patients vulnerable to hypo and hyperglycemic episodes." The American Association of Clinical Endocrinologists formally asked the FDA to act on this issue, "Because of the highly variable quality of the meters and the glucose testing strips in widespread use, the safety of our patients who depend upon those meters is threatened."  

Pepex CEO, Steve Collins, offered, "We expect the company's game-changing biosensor technology, packaged within our easy to use, one-button blood glucose meter, to deliver the accuracy required to meet or exceed future FDA standards. Trio's unique sensor design minimizes operator technique which can lead to user errors and affect the accuracy of glucose readings."

Approximately 60% of diabetics interviewed for the research said they would definitely replace their current meters with the Pepex Trio for the new technology's accuracy and convenience benefits.  As a result, Frost & Sullivan estimates that Pepex has a significant 5 year revenue opportunity, in the blood glucose monitoring market segment.  In addition, the breakthrough electrochemical biosensors are applicable to a variety of additional markets outside of glucose.

Pepex is a privately held a medical device company specializing in the development, manufacturing, and marketing of disposable, miniaturized electrochemical biosensors.  The company protects its market opportunities with 64 patents which encompass a broad spectrum of proprietary technology including: sensor chemistry and architecture, wireless sensor communications and laser welding manufacturing processes.  Pepex biosensors are the heart of a pipeline of life altering products for medical diagnostics and intervention.  The company is led by a team of business and scientific professionals experienced in the biomedical field and populated by a development staff with a successful track record of delivering next generation biomedical devices to market.  For more information, please visit www.pepex.com.  

For more information about this topic, or to schedule an interview with Joseph Driver, please call Andrea Skov at 408.888.3338 or e-mail Andrea at andrea.skov@pepex.com


'/>"/>
SOURCE Pepex Biomedical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Frost & Sullivan: Western European Markets Confirm Undisputed Convenience and Cost Benefit of Custom Procedure Trays
2. Mennen Medical Receives Frost & Sullivan 2009 European Patient Monitoring Technology Leadership Award
3. Frost & Sullivan Lauds Viatronix as European Medical Imaging Emerging Company of the Year
4. Frost & Sullivan Identifies Focus on Quality Management and Adoption of a Full-service Model as Keys to the Growth of the European CRO Market
5. Widening Application Range to Boost MRI Markets in Eastern Europe, Says Frost & Sullivan
6. Lifesciences IT Spending to Experience Mature Growth Rates Despite Economic Slowdown, Declares Frost & Sullivan
7. Frost & Sullivan Recognizes Holst Centre and imec for Its Path Breaking Wearable Energy Harvester Technology
8. Frost & Sullivan Recognizes Japan Stent Technology for Its Pioneering Coronary Stent Design
9. Central and Eastern European Healthcare Markets Hold Strong Potential for Growth Despite the Economic Slowdown, Says Frost & Sullivan
10. Frost & Sullivan Recognizes Fovia for its HDVR(R) Platform - A Disruptive Technology Breakthrough
11. Frost & Sullivan Recognizes IntelligentMDx for Its Commitment to the Advancement of Healthcare and Diagnostics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... HOUSTON , June 23, 2016  MedSource ... platform as its e-clinical software solution of choice.  ... the best possible value to their clients by ... nowEDC.  The preferred relationship establishes nowEDC as the ... pricing for MedSource,s full-service clients.  "nowEDC has long ...
(Date:6/23/2016)... -- In a startling report released today, National Safety Council ... comprehensive, proven plan to eliminate prescription opioid overdoses. Prescription ... are tackling the worst drug crisis in recorded U.S. history, assigned ... Kentucky , New Mexico , ... 28 failing states, three – Michigan , ...
(Date:6/23/2016)... , June 23, 2016 Research ... Pharma News Issue 52" report to their offering. ... in influenza treatment creates a favourable commercial environment for MedImmune ... growing patient base that will serve to drive considerable growth ... vaccine would serve to cap sales considerably, but development is ...
Breaking Medicine Technology:
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... Austin residents ... the American College of Mohs Surgery and to Dr. Russell Peckham for medical and ... highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed ...
(Date:6/25/2016)... , ... June 25, 2016 , ... As a lifelong ... Cum Laude and his M.D from the David Geffen School of Medicine at UCLA. ... to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai ...
(Date:6/24/2016)... ... 2016 , ... A recent article published June 14 on E ... goes on to state that individuals are now more comfortable seeking to undergo not ... as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension Association ... it will receive two significant new grants to support its work to advance ... 25th anniversary by recognizing patients, medical professionals and scientists for their work in ...
(Date:6/24/2016)... NY (PRWEB) , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin ... companies that call for a minimum wage raise to $12 an hour by 2020 and ... This will restore the lost value of the minimum wage, assure the wage floor does ...
Breaking Medicine News(10 mins):